Citius Pharmaceuticals GAAP EPS of -$3.38
Source: SeekingAlpha
2025-12-23 16:35:04 ET
More on Citius Pharmaceuticals
- Citius Pharmaceuticals GAAP EPS of -$3.38 misses by $0.25
- Citius Oncology announces $18 million registered direct offering
- Seeking Alpha’s Quant Rating on Citius Pharmaceuticals
- Historical earnings data for Citius Pharmaceuticals
- Financial information for Citius Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Citius Pharmaceuticals GAAP EPS of -$3.38
Citius Pharmaceuticals Inc.
NASDAQ: CTXR
CTXR Trading
-9.93% G/L:
$0.881 Last:
1,501,224 Volume:
$1.025 Open:
CTXR Latest News
March 10, 2026 08:47:00 am
Citius Oncology Announces Positive Topline Results from Investigator?Initiated Phase 1 Study of LYMPHIR(TM) in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
February 24, 2026 08:00:00 am
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
February 13, 2026 03:01:28 pm
Citius Pharmaceuticals Reports First Revenue Following LYMPHIR(TM) Launch
February 13, 2026 08:00:00 am
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)
CTXR Stock Data
$17,182,352
18,541,285
0.66%
11
N/A
Biotechnology & Life Sciences
Healthcare
US
Cranford
